Executive Leadership





Chris Pak

Koon Yan "Chris" Pak, Ph.D.

Chief Executive Officer and Chairman of the Board

Dr. Chris Pak brings three decades of experience in the biopharmaceutical industry. Chris was formerly with Centocor, now a subsidiary of Johnson and Johnson, where he invented and developed novel radiopharmaceuticals and participated in the filing of twelve IND applications for cancer and cardiovascular diseases. He has founded and led multiple societies promoting Nuclear Medicine and Molecular Imaging and entrepreneurship organizations.

Dr. Pak has published more than eighty articles and holds numerous patents on therapeutics and diagnostics. His awards include the 2019 Ernst & Young Entrepreneur of the Year Finalist of Greater Philadelphia, Asian Chamber of Commerce Outstanding Asian American Business Award, Ben Franklin Emerging Business Award, State University of New York Alumni Honor Roll, and the 2014 Lifetime Achievement Award from the Chinese American Society of Nuclear Medicine and Molecular Imaging.

Ji Li

Steven Brem, MD.

Chief Medical Officer

Dr. Brem is the Chief of Neurosurgical Oncology, Co-director of Penn Brain Tumor Center and Professor of Neurosurgery at University of Pennsylvania, Perelman School of Medicine. Dr. Brem is a renowned clinical research scientist who sits on the scientific/medical advisory boards of several cancer research associations including American Association of Cancer Research, American Brain Tumor Association and Brain Tumor Action Network among others. Dr. Brem has extensive clinical research experience in many types of tumors. He has reviewed and approved 127 tumor trial protocols in University of Pennsylvania and at Moffitt Cancer Center. Dr. Brem is currently the principle investigator of six cancer trials, including two NIH funded and four industry sponsored trials. He has published more than 100 clinical research articles in peer-reviewed journals and presented more than 100 posters in medical conferences such as ASCO (American Society of Clinical Oncology).

Chris Pak

Ji Li, Ph.D.

Chief Operating Officer, Board Director

An accomplished business creator, Dr. Li has orchestrated investment in and headed multiple life science businesses. In addition to his role as COO at MTTI, Dr. Li is President & CEO and co-founder of UFOVAX, Inc. commercializing Scripps Institute’s one component, self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology generating promising candidates for HIV, HCV, Ebola, RSV, MERS and, most recently, COVID-19.

Following his earlier tenure as VP R&D of Rhodia Asia Pacific he became Managing Director, M&A, Technology Development and Pharmaceutical Division and later Group President & CEO for the Feixiang Group. He continues as a Principal in Comway Capital and serves as Board Director of several Biotech startup companies




Jeffrey A. Mattis

Jeffrey A. Mattis, Ph.D.

Senior Vice President of Scientific & Regulatory Affairs, Board Director

Dr. Mattis is a biopharmaceutical executive with more than 30 years’ experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.




Brian Gray

Brian D. Gray, Ph.D.

Senior Vice President of Research

Dr Gray has more than 25 years’ experience in the design and synthesis of novel compounds for biomedical research, diagnostics and drug delivery, with special expertise in fluorescent dyes and lipophilic agents. Following a research career at SmithKline Beckman, Dr. Gray co-founded Zynaxis, Inc., a biotech, as Director of Medicinal Chemistry. Later as V.P. of Chemical Research for PTI Research, Inc., he provided contract and custom chemistry services for life sciences and designed novel research reagents for neuronal tract tracing (NeuroVue® dyes) and cell tracking (CellVue® dyes). Dr. Gray earned a Ph.D. from the University of Dundee, Scotland, and carried out post-doctoral research in complex organic molecule synthesis at Oregon State University. He has been Principal Investigator in multiple grants.




Michael Silvon

Michael Silvon, Ph.D., MBA

Senior Vice President of Business Development

Dr. Silvon has driven profitable, pragmatic life sciences operations over the breadth of small and large molecule drug development; creating, fixing and growing multiple high science, heavily regulated businesses as a senior executive for Charles River Labs, Bioanalytical Systems and ICI/Zeneca. He orchestrated six acquisitions and integrated and ran businesses for three of these long-term. As VP Global Biopharmaceutical Services for Charles River Labs, he restructured and consolidated five global sites into a global leader in molecular biology, virology and microbiology services. Mike advises Chronic Airways Therapeutics and also serves as a Director for Claro Labs and Spark Insights.




Michael Silvon

Jianwei Xu, Ph.D

Chief Business Officer

Dr. Xu has a decade of consulting and investment experience in the pharmaceutical industry. His most recent positions include Director of Decision Analysis and Portfolio Management at Johnson & Johnson Pharmaceutical R&D and Decision Analysis Advisor at Chevron. Previously, as an associate at McKinsey & Company he supported major pharmaceutical companies, planning and implementing strategies to optimize competitive position. He has identified and evaluated major trends impacting Pharmaceutical industry valuation and guides clients to exploit them to unlock value.

Dr. Xu has extensive experience in competitive intelligence and strategic development. He directed multi-national programs generating competitive intelligence research and analysis, supporting pharmaceutical planning, R&D, BD&L and commercial. He is responsible for the equity research of a start-up hedge fund.




Board Of Directors





Chris Pak

Koon Yan "Chris" Pak, Ph.D.

Chief Executive Officer and Chairman of the Board

Dr. Chris Pak brings three decades of experience in the biopharmaceutical industry. Chris was formerly with Centocor, now a subsidiary of Johnson and Johnson, where he invented and developed novel radiopharmaceuticals and participated in the filing of twelve IND applications for cancer and cardiovascular diseases. He has founded and led multiple societies promoting Nuclear Medicine and Molecular Imaging and entrepreneurship organizations.

Dr. Pak has published more than eighty articles and holds numerous patents on therapeutics and diagnostics. His awards include the 2019 Ernst & Young Entrepreneur of the Year Finalist of Greater Philadelphia, Asian Chamber of Commerce Outstanding Asian American Business Award, Ben Franklin Emerging Business Award, State University of New York Alumni Honor Roll, and the 2014 Lifetime Achievement Award from the Chinese American Society of Nuclear Medicine and Molecular Imaging.

Chris Pak

Ji Li, Ph.D.

Chief Operating Officer, Board Director

An accomplished business creator, Dr. Li has orchestrated investment in and headed multiple life science businesses. In addition to his role as COO at MTTI, Dr. Li is President & CEO and co-founder of UFOVAX, Inc. commercializing Scripps Institute’s one component, self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology generating promising candidates for HIV, HCV, Ebola, RSV, MERS and, most recently, COVID-19.

Following his earlier tenure as VP R&D of Rhodia Asia Pacific he became Managing Director, M&A, Technology Development and Pharmaceutical Division and later Group President & CEO for the Feixiang Group. He continues as a Principal in Comway Capital and serves as Board Director of several Biotech startup companies




Jeffrey A. Mattis

Jeffrey A. Mattis, Ph.D.

Senior Vice President of Scientific & Regulatory Affairs, Board Director

Dr. Mattis is a biopharmaceutical executive with more than 30 years’ experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.




Chris Pak

Dr. Peter E. Grebow, Ph.D.

Board Director

Founder and President of P.E. Grebow Consulting, Inc. since 2011. Dr. Grebow has more than twenty-five years of experience in the pharmaceutical industry, last serving as an EVP of Research & Development of Eagle Pharmaceuticals Inc.

Earlier Dr. Grebow held senior executive roles with Cephalon, Inc.; EVP Worldwide Technical Operations, EVP of Cephalon Ventures and EVP of Worldwide Technical Operations of Cima Labs Inc. EVP of at Cephalon, Inc. Peter also served as VP of Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc.

He serves/has served as a Director of Inspyr Therapeutics, Inc. (Chair), Complexa, Inc., Q Therapeutics, Inc., Optimer Pharmaceuticals, Inc. and Harrington Discovery Institute




Jeffrey A. Mattis

Sean Wang

Founder & CEO, B&W TEK, Board Director

An accomplished entrepreneur, inventor, scientist and engineer Dr. Wang has launched, incubated, and financed more than a dozen companies, most of them based on the generation, manipulation, and detection of light.

He is CEO of B&W TEK Inc, a leading photonic instrument company producing analytical instrumentation, medical systems and lasers, recently acquired by Metrohm Group, together becoming one of the largest solutions-providers for mobile spectroscopy.

Sean holds advanced degrees in Physics and Electrical Engineering. He is the author of many scientific publications and holds 60 US and international patents, received or filed. He is a fellow of the American Society of Laser Medicine and Surgery. Recently named Entrepreneur in Residence with multiple honors for innovation, Dr. Wang is an adjunct professor and a member of the advisory council at the University of Delaware. He is founding Director of the PBM Institute and Co-founder and Chairman of LiteCure, both focused on innovations in Photonic Based Medicine at the UD STAR Campus.




Scientific Advisors





Chris Pak

H. William Strauss, M.D.

Clinical Director, Nuclear Medicine Service at Memorial Sloan-Kettering Cancer Center

Dr. Strauss is the Clinical Director, Nuclear Medicine Service at Memorial Sloan-Kettering Cancer Center. Formerly he was Professor of Radiology and Chief of Nuclear Medicine at Stanford University School of Medicine and Vice President of Bristol-Myers-Squibb. Earlier Dr. Strauss was Professor at the Harvard Medical School and Massachusetts General Hospital for almost two decades.

The recipient of numerous awards, his recent honors include the Distinguished Service Award of the Society of Nuclear Medicine and distinguished Johns Hopkins Nuclear Medicine Alumni Award. He has served on many national and international committees and boards such as Advisory Committee of Federal Drug Administration and Medical Expert Advisory Committee on Disciplinary Matters, Board of Registration in Medicine.

He serves on the editorial boards of the American Journal of Cardiology and Journal of Nuclear Medicine. He is the author of over 450 papers and articles and editors of several major b Performed and managed multiple research and clinical projects, resulting in 17 patents and multiple clinical procedures

Chris Pak

Sean Yan Xue Xian MD, DABNM

Senior Consultant Physician at Singapore General Hospital

Dr. Yan is an experienced senior consultant physician with Singapore General Hospital and a visiting consultant with National Cancer Center Singapore since 2015.

Earlier Dr. Yan trained at Chongqing Medical University, Vanderbilt University, Emory University and Mt. Sinai Hospital focused on oncology and nuclear medicine. He is a member, Joint Committee on Specialist Training examination committee, Ministry of Health, Singapore and Core Faculty in the Singhealth diagnostic radiology residency program, Singapore.




Jeffrey A. Mattis

Ban An Khaw, Ph.D.

Director of the Center for Drug Targeting and Analysis at Northeastern University

Dr. Khaw is a leading authority in cardiac imaging and new technology development. He has been with the Harvard Medical School and the Massachusetts General Hospital, Division of Nuclear Medicine, Department of Radiology and the Cardiac Unit for three decades and is currently Director of the Center for Drug Targeting and Analysis, at the Bouvè College of Pharmacy and Health Sciences at Northeastern University. Dr. Khaw is a pioneer in the application of immunological methods in the diagnosis of cardiovascular diseases. He co-developed Myoscint for myocardial infarct detection. He has chaired multiple symposia, authored nearly 300 publications and holds 15 patents. Currently, he is on the editorial boards of Bioconjugate Chemistry and American Journal of Nuclear Cardiology.




Chris Pak

Professor Fabian Kiessling, M.D., Ph.D.

Institute of Experimental Molecular Imaging at the Helmholtz Center of Applied Engineering of the RWTH-University

Professor Fabian Kiessling has headed the Institute of Experimental Molecular Imaging at the Helmholtz Center of Applied Engineering of the RWTH-University in Aachen, Germany since 2008.

Professor Kiessling studied Medicine, completed clinical training and received his Ph.D. from the University in Heidelberg. After residency in the German Cancer Research Center (DKFZ- Heidelberg) he joined the Department of Medical Physics in Radiology as leader of the Molecular Imaging group.

Dr. Kiessling authored more than 200 scientific publications and book chapters, edited two books and received several research awards, including the “Emil Salzer Prize for Cancer Research” and the “Richtzenhain Prize”. He serves on the Editorial board of several journals including Radiology, European Radiology, American Journal of Nuclear Medicine and Molecular Imaging, Current Medicinal Chemistry, Frontiers in Bioscience and the Open Organic Chemistry Journal. He is a founding member and/officer of multiple global radiology Societies and committees.







News

Posted 07/31/2020 - New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors
read more



Posted 07/10/2020 - Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
read more



Posted 07/10/2020 - First-in-Human Study of a Long-acting αvβ3Integrin Targeting Molecule 64Cu-NOTA-EB-RGD in Healthy Volunteers and GBM Patients
read more



Posted 07/10/2020 - Early Studies Show Multiple Cycles of EBTATE are Well Tolerated and Effective in Treating Neuroendocrine Tumors
read more



Posted 10/28/2019 - MTTI Receives Global Rights from NIH for Integrin-targeting Radiotherapeutics to treat GBM and Lung Cancer
read more



Posted 06/22 /2019 - Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors
read more



Posted 06/18/2019 - Molecular Targeting Technologies, Inc. Announces Closing of Series A Financing to Develop Novel Neuroendocrine Neoplasm Drug
read more



Posted 06/17/2019 - Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting
read more



Posted 05/13/2019 - EY Announces Chris Pak of Molecular Targeting Technologies, Inc. as Entrepreneur Of The Year® 2019 Award Finalist in Greater Philadelphia
read more



Posted 10/08/2018 - Molecular Targeting Technologies, Inc. Wins Exclusive License for Novel Neuroendocrine Neoplasm Drug from NIH.
read more



Posted 9/29/2017 - Molecular Targeting Technologies, Inc. Wins Award from “RESI Boston 2017” Innovation Challenge
read more



Posted 6/27/2017 - TumorVue Image Wins the 2017 MILabs Image of the Year Award
read more



Posted 12/05/2016 - MTTI announces that response of colorectal cancer to treatment can be detected as early as one day after treatment
read more



Posted 08/18/2016 - New milestone: 癌症治療新曙光 國衛院與泰緯生技攜手抗癌
read more



Posted 01/08/2016 - MTTI Receives Multimodality DPA Technology Patent
read more



Posted 05/15/2015 - MTTI receives expanded patent approval for 99mTc-Duramycin technology to target programmed cell death
read more



Posted 05/08/2015 - World news on Novel Cancer Therapeutic



Posted 05/06/2015 - MTTI announces the capability of PSVue 794 to non-invasively image arthritis
read more



Posted 05/06/2015 - MTTI announces the capability of PSVue 794 to non-invasively image arthritis
read more



Posted 05/06/2015 - MTTI announces the capability of PSVue 794 to non-invasively image arthritis
read more



Posted 04/22/2015 - MTTI Smith Molecular Probe on WSBT View Video




Posted 04/22/2015 - Dr. Bradley Smith speaks about the potential clinical applications of Cell-Death Imaging Agent View Video




Posted 04/18/2015 - 國家衛生研究院暨美國Molecular Targeting Technologies公司於2015美國癌症研究協會(AACR)共同發表新穎癌症治療法合作案之研發成果
read more



Posted 04/17/2015 - MTTI and National Health Research Institutes Present a Novel Cancer Therapeutic at 2015 AACR
read more



Posted 10/24/2014 - MTTI receives patent approval for technology to identify dead and dying cells in patients
read more



Posted 08/04/2014 - MTTI and National Health Research Institutes Have Joined Forces in Developing Novel Cancer Therapeutics
read more



Posted 08/04/2014 - 國 家衛生研究院暨美國 家衛生研究院暨美國 家衛生研究院暨美國 家衛生研究院暨美Molecular Targeting Molecular Targeting Molecular Targeting 公司 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合
read more



Posted 06/13/2014 - Chris Pak received 2014 Lifetime Achievement Award from CASNMMI
read more



Posted 02/26/14 - Philadelphia Business Journal Recognizes MTTI for 2013 Innovation Award
read more



Posted 06/21/13 - Real time assessment of tumor response presentation wins the Innovation Competition
read more



Posted 11/28/12 - Notre Dame and MTTI Awarded Patent for Fluorescent Dye Technology
read more



Posted 8/2/12 - MTTI licenses Novel Targeting Agent from Medical College of Wisconsin
read more



Posted 5/10/11 - MTTI licenses robust NIR dye technology from Massachusetts General Hospital
read more



Posted 10/12/10 - Jefferson Awarded Multi-Million Dollar NIH Grant
read more



Posted 9/22/10- Zn_DPA Cardiac Imaging Study Wins Competition
read more



Posted 3/19/10 - University of Notre Dame and MTTI in Deal
read more



Posted 3/1/10 - Molecular Targeting Technologies, Inc. Licenses Cell Targeting Technology from the University of Notre Dame
read more



Posted 3/2/09 - LI-COR Sciences and MTTI Introduce CellVue® Dye Kits for Fluorescent Labeling of Cell Membranes
read more



Posted 8/23/08 - MTTI has B-Bridge Inc. as a distributor for Japan.
read more



Posted 8/22/08 - MTTI has engaged Dundee Cell Products as a distributor for Europe.
read more



Posted 4/22/08 - MTTI will collaborate with Bexion to develop a novel nanovesicle for molecular imaging of tumors.
read more



Posted 1/8/08 - MTTI and GENSEEN Partner to Develop Breast Cancer Gene Imaging Agent
read more



FCOI Policy